title: Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I.
abstract: In order to investigate the effect and mechanism of action of rosuvastatin on atherosclerotic lesion in a Wistar rat model, 16 Wistar rats were fed a cholesterol-rich, vitamin D3 overload diet and underwent balloon injury of the aorta. One day prior to injury, half of the rats began rosuvastatin treatment (5mg/kg/d) via oral gavage. Eight control rats received a basal diet and sham operation. After 14 weeks of treatment, the animals were sacrificed. Blood was collected to measure lipid and angiotensin II (Ang II) levels and morphologic analysis was performed on the aorta. Scavenger receptor-class B type I (SR-BI), Ang II type-1 (AT1) receptor and phosphorylated extracellular signal regulated kinase 1/2 (p-ERK1/2) protein and mRNA levels were measured via Western blot and real time reverse transcriptase polymerase chain reaction, respectively. Spearman's rank correlation was utilized to examine the relationships between SR-BI and Ang II or AT1 receptor expression. The atherosclerosis model group demonstrated an increase in plasma lipid levels and aortic plaque formation. After 14 weeks of treatment with rosuvastatin, there was a significant decrease in plasma lipid and Ang II levels accompanied by an improvement in aortic lesions. Rosuvastatin increased the expression of SR-BI but significantly inhibited the expression of AT1 receptor and p-ERK1/2. SR-BI protein expression was inversely correlated with both the level of Ang II and expression of the AT1 receptor. In conclusion, rosuvastatin attenuates atherosclerosis in the Wistar rat model, and its anti-atherosclerotic activity may be through upregulation of SR-BI expression and inhibition of p-ERK1/2 levels and AT1 receptor expression.
authors: Department of Cardiology, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao 266003, China.
authors: Yonghong
authors: Y
authors: Li
authors: Department of Emergency, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao 266003, China.
authors: Qixin
authors: Q
authors: Wang
authors: Department of Emergency, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao 266003, China.
authors: Jingwei
authors: J
authors: Zhou
authors: Department of Cardiology, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao 266003, China.
authors: Qingke
authors: Q
authors: Xu
authors: Department of Cardiology, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao 266003, China.
authors: Xianming
authors: X
authors: Chu
authors: Department of Cardiology, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao 266003, China.
authors: Tingru
authors: T
authors: Sun
authors: Department of Cardiology, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao 266003, China.
authors: Xu
authors: X
authors: Liu
authors: Department of Cardiology, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao 266003, China. Electronic address: liyonghong-66@163.com.
authors: Shanglang
authors: S
authors: Cai
mesh_terms: D000804:Angiotensin II / Q000378:metabolism; D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D050197:Atherosclerosis / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D005464:Fluorobenzenes / Q000494:pharmacology* / Q000627:therapeutic use; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics / Q000378:metabolism; D000068718:Rosuvastatin Calcium; D051122:Scavenger Receptors, Class B / Q000235:genetics / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D015854:Up-Regulation
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; C495125:Scarb1 protein, rat; D051122:Scavenger Receptors, Class B; D013449:Sulfonamides; D014280:Triglycerides; D000804:Angiotensin II; D000068718:Rosuvastatin Calcium; D002784:Cholesterol; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
keywords: Atherosclerosis; Rosuvastatin; Rosuvastatin (PubChem CID: 12136802); Scavenger receptor class B type I